With more than 30 years of experience spanning global pharma, emerging biotech, and the evolving field of personalized medicine, Bracken Senior Partner Dr. David Krause has helped shape the clinical and regulatory landscape across therapeutic areas—from vaccines and anti-infectives to neuropsychiatry and oncology.

As a physician, former Chief Medical Officer, and trusted development advisor, David brings a uniquely humanist and interdisciplinary lens to the science and strategy of drug development.

In this episode of Fractals: Life Science Conversations, David and host Colin Miller explore:

• How leadership style must evolve from large pharma to small biotech—and why succession planning matters more than you think.
• The future of personalized medicine in CNS and oncology—and how AI, genetics, and neuroplasticity are reshaping treatment paradigms.
• What pharma can learn from infectious disease: why psychiatry is just now catching up to decades-old precision strategies in anti-infectives.
• Reflections on partnering with the FDA, lessons learned from vaccine development, and the clinical promise of psychedelics.

Listen to Fractals on your favorite podcast platform, and contact Bracken to learn how our cross-functional teams can support your clinical, medical, and regulatory strategy.